GCK-MODY: Clinical case report
https://doi.org/10.62751/2713-0177-2024-5-3-12
Abstract
Currently, monogenic forms of diabetes mellitus account for up to 6.5% of all cases of diabetes in children and adolescents. Among the 14 currently identified types of MODY diabetes, the most common are HNF4a-, GCK-, and HNF1a-MODY. Among the latter, GCK-MODY has the mildest course, often not requiring drug therapy, with a favorable prognosis in terms of micro- and macrovascular complications. The development of molecular genetics makes it possible to more accurately verify various types of diabetes mellitus, predict the course of the disease, determine treatment tactics, and conduct medical genetic counseling for families. The aim of the article: to present follow-up data from a family with GCK-MODY diabetes.
About the Authors
R. I. Malievskaya
Bashkir State Medical University
Russian Federation
Russian Federation
Ramzia I. Malievskaya – assistant at the Department of Endocrinology
Ufa
O. A. Malievskiy
Bashkir State Medical University
Russian Federation
Russian Federation
Oleg A. Malievsky – MD, Professor of the Department of Hospital Pediatrics
Ufa
T. V. Morugova
Bashkir State Medical University
Russian Federation
Russian Federation
Tatyana V. Morugova – MD, Professor, Head of the Department of Endocrinology
Ufa
References
1. Johansson BB, Irgens HU, Molnes J et al. Targeted next‐generation sequencing reveals MODY in up to 6.5% of antibody‐negative diabetes cases listed in the Norwegian childhood diabetes registry. Diabetologia. 2017; 60(4): 625–35. doi: 10.1007/s00125-016-4167-1.
2. Shepherd M, Shields B, Hammersley S et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care. 2016; 39(11): 1879–88. doi: 10.2337/dc16-0645.
3. Greeley SAW, Polak M, Njщlstad PR et al. ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2022; 23(8): 1188–211. doi: 10.1111/pedi.13426.
4. Stanik J, Dusatkova P, Cinek O et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia. 2014; 57(3): 480–84. doi: 10.1007/s00125-013-3119-2.
5. Mozzillo E, Salzano G, Barbetti F et al. Survey on etiological diagnosis of diabetes in 1244 Italian diabetic children and adolescents: Impact of access to genetic testing. Diabetes Res Clin Pract. 2015; 107(3): e15-8. doi: 10.1016/j.diabres.2015.01.003.
6. Сечко Е.А., Кураева Т.Л., Зильберман Л.И. с соавт. Неиммунный сахарный диабет у детей, обусловленный гетерозиготными мутациями в гене глюкокиназы (GCK-MODY): анализ данных 144 пациентов. Сахарный диабет. 2022; 25(2): 145–154. doi: 10.14341/DM12819.
7. Кураева Т.Л., Сечко Е.А., Зильберман Л.И., и др. Молекулярно-генетические и клинические варианты MODY2 и MODY3 у детей в России. Проблемы эндокринологии. 2015; 61(5): 14–25. doi: 10.14341/probl201561514-25.
8. Zhou Y, Wang S, Wu J, Dong J, Liao L. MODY2 in Asia: analysis of GCK mutations and clinical characteristics. Endocr Connect. 2020 May;9(5):471-478. doi: 10.1530/EC-20-0074.
9. Li Z, Li K, Sun Y et al. Mutations in GCK may lead to MODY2 by reducing glycogen synthesis. Adv Biol (Weinh). 2022; 6(11): e2200097. doi: 10.1002/adbi.202200097.
10. Овсянникова А.К., Шахтшнейдер Е.В., Иванощук Д.Е. с соавт. Течение GCKMODY диабета у лиц старше 18 лет: данные проспективного наблюдения. Сахарный диабет. 2021; 24(2): 133–140. doi: 10.14341/DM12319.
11. Steele AM, Shields BM, Wensley KJ et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged mild hyperglycemia. JAMA. 2014; 311(3): 279–86. doi: 10.1001/jama.2013.283980.
12. Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57:54–56. doi: 10.1007/s00125-013-3075-x.
13. Fendler W, Malachowska B, Baranowska‐Jazwiecka A et al. Population‐based estimates for double diabetes amongst people with glucokinase monogenic diabetes, GCK‐MODY. Diabet Med. 2014; 31(7): 881–83. doi: 10.1111/dme.12449.
14. Chakera AJ, Steele AM, Gloyn AL et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care. 2015; 38(7): 1383–92. doi: 10.2337/dc14-2769.
15. Hulín J, Skopkova M, Valkovicova T et al. Clinical implications of the glucokinase impaired function – GCK MODY today. Physiol Res. 2020; 69(6): 995–1011. doi: 10.33549/physiolres.934487.
Review
For citations:
Malievskaya R.I., Malievskiy O.A., Morugova T.V. GCK-MODY: Clinical case report. FOCUS. Endocrinology. 2024;5(3):92-95. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-3-12
Views:
103
Email this article 